{
    "clinical_study": {
        "@rank": "30124", 
        "arm_group": [
            {
                "arm_group_label": "Silybin  + vitamin E  + phospholipids complex", 
                "arm_group_type": "Active Comparator", 
                "description": "Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "one placebo pill per day for 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting\n      mainly from the complications of cirrhosis and HCC.\n\n      The investigators' aim will be to evaluate the impact on of supplementation with a new\n      pharmaceutical complex of silybin-vitamin E-phospholipids in patients with chronic hepatitis\n      C treated with Pegylated-Interferon-\u03b12b plus Ribavirin."
        }, 
        "brief_title": "Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Liver Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Liver Cirrhosis", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older,\n\n          -  infection by HCV\n\n          -  under treatment with pegylated interferon 2 alpha and ribavirin\n\n        Exclusion Criteria:\n\n          -  other liver diseases\n\n          -  cancer\n\n          -  severe jaundice\n\n          -  pulmonary and renal chronic diseases\n\n          -  prostatic diseases\n\n          -  autoimmune diseases\n\n          -  diabetes mellitus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935817", 
            "org_study_id": "unict11/1997"
        }, 
        "intervention": [
            {
                "arm_group_label": "Silybin  + vitamin E  + phospholipids complex", 
                "intervention_name": "Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin E", 
                "Alpha-Tocopherol", 
                "Tocopherols", 
                "Tocotrienols", 
                "Silybin", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Catania", 
                    "country": "Italy", 
                    "state": "Sicily", 
                    "zip": "95125"
                }, 
                "name": "Cannizzaro Hospital"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "other_outcome": [
            {
                "description": "serum marker of liver fibrosis", 
                "measure": "metalloproteinase 2", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "serum marker of liver fibrosis", 
                "measure": "amino-terminal pro-peptide of type III procollagen", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "serum marker of liver fibrosis", 
                "measure": "tissue inhibitor of matrix metalloproteinase type I", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "serum marker of liver fibrosis", 
            "measure": "transforming growth factor beta", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935817"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Catania", 
            "investigator_full_name": "Mariano Malaguarnera", 
            "investigator_title": "A.P.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "serum marker of liver fibrosis", 
            "measure": "hyaluronic acid", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "University of Catania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Catania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}